$7.01 Billion is the total value of Bellevue Group AG's 198 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS INC | $113,662,320 | +23.3% | 4,013,500 | 0.0% | 1.62% | +21.2% | |
| PODD | INSULET CORP | $93,305,094 | -9.6% | 323,594 | 0.0% | 1.33% | -11.1% | |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $61,074,000 | -5.7% | 1,800,000 | 0.0% | 0.87% | -7.3% | |
| ALGN | ALIGN TECHNOLOGY INC | $60,521,950 | +5.8% | 171,140 | 0.0% | 0.86% | +4.0% | |
| ARVN | ARVINAS INC | $52,792,140 | -9.2% | 2,127,000 | 0.0% | 0.75% | -10.7% | |
| MGNX | MACROGENICS INC | $51,413,035 | -25.4% | 9,609,913 | 0.0% | 0.73% | -26.7% | |
| GMED | GLOBUS MED INCcl a | $38,560,783 | +5.1% | 647,645 | 0.0% | 0.55% | +3.4% | |
| PROCEPT BIOROBOTICS CORP | $26,212,626 | +24.5% | 741,517 | 0.0% | 0.37% | +22.2% | ||
| HOLX | HOLOGIC INC | $23,492,312 | +0.3% | 290,136 | 0.0% | 0.34% | -1.5% | |
| FATE | FATE THERAPEUTICS INC | $23,113,508 | -16.5% | 4,855,779 | 0.0% | 0.33% | -17.9% | |
| BEAM | BEAM THERAPEUTICS INC | $22,204,793 | +4.3% | 695,421 | 0.0% | 0.32% | +2.6% | |
| RMD | RESMED INC | $21,473,088 | -0.2% | 98,275 | 0.0% | 0.31% | -1.9% | |
| EPIX | ESSA PHARMA INC | $21,326,174 | -9.1% | 7,898,583 | 0.0% | 0.30% | -10.6% | |
| GBIO | GENERATION BIO CO | $19,911,540 | +27.9% | 3,620,280 | 0.0% | 0.28% | +25.7% | |
| PHR | PHREESIA INC | $19,804,630 | -4.0% | 638,653 | 0.0% | 0.28% | -5.4% | |
| TXG | 10X GENOMICS INC | $18,133,817 | +0.1% | 324,746 | 0.0% | 0.26% | -1.5% | |
| WVE | WAVE LIFE SCIENCES LTD | $16,359,827 | -15.9% | 4,494,458 | 0.0% | 0.23% | -17.4% | |
| SRRK | SCHOLAR ROCK HLDG CORP | $16,135,789 | -5.7% | 2,140,025 | 0.0% | 0.23% | -7.3% | |
| DOCS | DOXIMITY INCcl a | $15,260,658 | +5.1% | 448,579 | 0.0% | 0.22% | +3.3% | |
| NTRA | NATERA INC | $11,326,832 | -12.4% | 232,775 | 0.0% | 0.16% | -13.8% | |
| ESPR | ESPERION THERAPEUTICS INC NE | $5,849,487 | -12.6% | 4,208,264 | 0.0% | 0.08% | -14.4% | |
| NVRO | NEVRO CORP | $5,556,126 | -29.7% | 218,573 | 0.0% | 0.08% | -31.3% | |
| MTEM | MOLECULAR TEMPLATES INC | $5,390,401 | +26.3% | 11,230,003 | 0.0% | 0.08% | +24.2% | |
| OLK | OLINK HLDG ABsponsored ads | $4,492,950 | -16.8% | 239,624 | 0.0% | 0.06% | -17.9% | |
| ABC | AMERISOURCEBERGEN CORP | $3,061,561 | +20.2% | 15,910 | 0.0% | 0.04% | +18.9% | |
| GH | GUARDANT HEALTH INC | $2,942,653 | +52.7% | 82,197 | 0.0% | 0.04% | +50.0% | |
| SIGHT SCIENCES INC | $2,370,432 | -5.3% | 286,284 | 0.0% | 0.03% | -5.6% | ||
| KOS | KOSMOS ENERGY LTD | $1,906,617 | -19.5% | 318,300 | 0.0% | 0.03% | -20.6% | |
| LH | LABORATORY CORP AMER HLDGS | $1,686,414 | +5.2% | 6,988 | 0.0% | 0.02% | +4.3% | |
| GDX | VANECK ETF TRUSTgold miners etf | $993,630 | -6.9% | 33,000 | 0.0% | 0.01% | -6.7% | |
| SPY | SPDR S&P 500 ETF TRtr unit | $797,904 | +8.3% | 1,800 | 0.0% | 0.01% | 0.0% | |
| GOOG | ALPHABET INCcap stk cl c | $725,820 | +16.3% | 6,000 | 0.0% | 0.01% | +11.1% | |
| SEER | SEER INC | $581,288 | +10.6% | 136,133 | 0.0% | 0.01% | 0.0% | |
| XOP | SPDR SER TRs&p oilgas exp | $502,437 | +1.0% | 3,900 | 0.0% | 0.01% | 0.0% | |
| GDXJ | VANECK ETF TRUSTjunior gold mine | $178,300 | -9.7% | 5,000 | 0.0% | 0.00% | 0.0% | |
| MCHI | ISHARES TRmsci china etf | $183,434 | -10.3% | 4,100 | 0.0% | 0.00% | 0.0% | |
| ASR | GRUPO AEROPORTUARIO DEL SUREspon adr ser b | $37,488 | -9.4% | 135 | 0.0% | 0.00% | 0.0% | |
| JMIA | JUMIA TECHNOLOGIES AGsponsored ads | $61,560 | +4.0% | 18,000 | 0.0% | 0.00% | 0.0% | |
| INFY | INFOSYS LTDsponsored adr | $18,159 | -7.9% | 1,130 | 0.0% | 0.00% | – | |
| KZR | KEZAR LIFE SCIENCES INC | $24,500 | -21.7% | 10,000 | 0.0% | 0.00% | – | |
| UMC | UNITED MICROELECTRONICS CORPspon adr new | $21,287 | -9.9% | 2,698 | 0.0% | 0.00% | – | |
| EVTC | EVERTEC INC | $27,217 | +9.1% | 739 | 0.0% | 0.00% | – | |
| EQIX | EQUINIX INC | $31,358 | +8.7% | 40 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.